Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
3.480
-0.200 (-5.43%)
Jun 3, 2026, 12:18 PM EDT - Market open
Cabaletta Bio Employees
As of March 31, 2026, Cabaletta Bio had 158 total employees, including 156 full-time and 2 part-time employees. The number of employees decreased by 9 or -5.39% compared to the same quarter last year.
Employees
158
Change
-9
Growth
-5.39%
Revenue / Employee
n/a
Profits / Employee
-$1,110,304
Market Cap
567.43M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 158 | -9 | -5.39% | 156 | 2 |
| Dec 31, 2025 | 156 | -8 | -4.88% | 154 | 2 |
| Sep 30, 2025 | 151 | -4 | -2.58% | 148 | 3 |
| Jun 30, 2025 | 170 | 32 | 23.19% | 167 | 3 |
| Mar 31, 2025 | 167 | 47 | 39.17% | 163 | 4 |
| Dec 31, 2024 | 164 | 61 | 59.22% | 161 | 3 |
| Sep 30, 2024 | 155 | 61 | 64.89% | 154 | 1 |
| Jun 30, 2024 | 138 | 59 | 74.68% | 136 | 2 |
| Mar 31, 2024 | 120 | 53 | 79.10% | 118 | 2 |
| Dec 31, 2023 | 103 | 43 | 71.67% | 101 | 2 |
| Sep 30, 2023 | 94 | 35 | 59.32% | 92 | 2 |
| Jun 30, 2023 | 79 | 21 | 36.21% | 77 | 2 |
| Mar 31, 2023 | 67 | 10 | 17.54% | 66 | 1 |
| Dec 31, 2022 | 60 | 6 | 11.11% | 58 | 2 |
| Sep 30, 2022 | 59 | 12 | 25.53% | 57 | 2 |
| Jun 30, 2022 | 58 | 19 | 48.72% | 57 | 1 |
| Mar 31, 2022 | 57 | 21 | 58.33% | 56 | 1 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Arvinas | 246 |
| Prime Medicine | 146 |
| Aclaris Therapeutics | 73 |
| Tectonic Therapeutic | 60 |
| Altimmune | 57 |
| Candel Therapeutics | 55 |
| Design Therapeutics | 54 |
CABA News
- 1 hour ago - Cabaletta Bio presents new data for rese-cel in autoimmune diseases - TheFly
- 4 hours ago - Cabaletta Bio Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 hours ago - Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress - GlobeNewsWire
- 2 days ago - Cabaletta Bio Proxy statement: Proxy filing - Filings
- 14 days ago - Cabaletta Bio Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 20 days ago - Cabaletta Bio presents new clinical data for rese-cel - TheFly
- 20 days ago - Cabaletta Bio reports Q1 EPS (39c), consensus (39c) - TheFly
- 20 days ago - Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire